A citation-based method for searching scientific literature

Beoung Hun Lee, Suhn K Rhie. Epigenetics Chromatin 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Comprehensive analysis of CpG islands in human chromosomes 21 and 22.
Daiya Takai, Peter A Jones. Proc Natl Acad Sci U S A 2002
50

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
50

Epigenomics and breast cancer.
Pang-Kuo Lo, Saraswati Sukumar. Pharmacogenomics 2008
117
50

Most mammalian mRNAs are conserved targets of microRNAs.
Robin C Friedman, Kyle Kai-How Farh, Christopher B Burge, David P Bartel. Genome Res 2009
50

A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands.
M Frommer, L E McDonald, D S Millar, C M Collis, F Watt, G W Grigg, P L Molloy, C L Paul. Proc Natl Acad Sci U S A 1992
50

High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer.
Kevin Grosselin, Adeline Durand, Justine Marsolier, Adeline Poitou, Elisabetta Marangoni, Fariba Nemati, Ahmed Dahmani, Sonia Lameiras, Fabien Reyal, Olivia Frenoy,[...]. Nat Genet 2019
211
50


Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Charlotte Fribbens, Ben O'Leary, Lucy Kilburn, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Massimo Cristofanilli, Fabrice Andre, Sherene Loi, Sibylle Loibl,[...]. J Clin Oncol 2016
429
50

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zefei Jiang, Wei Li, Xichun Hu, Qingyuan Zhang, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng,[...]. Lancet Oncol 2019
102
50

Pharmacogenomics: the genetics of variable drug responses.
Dan M Roden, Russell A Wilke, Heyo K Kroemer, C Michael Stein. Circulation 2011
105
50

Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state.
Assaf Rotem, Oren Ram, Noam Shoresh, Ralph A Sperling, Alon Goren, David A Weitz, Bradley E Bernstein. Nat Biotechnol 2015
506
50

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
50


Triple-negative breast cancer molecular subtyping and treatment progress.
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu. Breast Cancer Res 2020
409
50

Whole genome sequencing identifies high-impact variants in well-known pharmacogenomic genes.
Jihoon Choi, Kelan G Tantisira, Qing Ling Duan. Pharmacogenomics J 2019
4
50

Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer.
Mahdieh Jadaliha, Xinying Zong, Pushkar Malakar, Tania Ray, Deepak K Singh, Susan M Freier, Tor Jensen, Supriya G Prasanth, Rotem Karni, Partha S Ray,[...]. Oncotarget 2016
117
50

Single-cell chromatin immunocleavage sequencing (scChIC-seq) to profile histone modification.
Wai Lim Ku, Kosuke Nakamura, Weiwu Gao, Kairong Cui, Gangqing Hu, Qingsong Tang, Bing Ni, Keji Zhao. Nat Methods 2019
91
50


Recent Advances in the Treatment of Breast Cancer.
Christy W S Tong, Mingxia Wu, William C S Cho, Kenneth K W To. Front Oncol 2018
171
50


Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Eric Hahnen, Bianca Lederer, Jan Hauke, Sibylle Loibl, Sandra Kröber, Andreas Schneeweiss, Carsten Denkert, Peter A Fasching, Jens U Blohmer, Christian Jackisch,[...]. JAMA Oncol 2017
213
50

Alteration of Epigenetic Regulation by Long Noncoding RNAs in Cancer.
Mariangela Morlando, Alessandro Fatica. Int J Mol Sci 2018
104
50

miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study.
Bethany N Hannafon, Angela Cai, Cameron L Calloway, Yi-Fan Xu, Roy Zhang, Kar-Ming Fung, Wei-Qun Ding. BMC Cancer 2019
63
50



A chromatin integration labelling method enables epigenomic profiling with lower input.
Akihito Harada, Kazumitsu Maehara, Tetsuya Handa, Yasuhiro Arimura, Jumpei Nogami, Yoko Hayashi-Takanaka, Katsuhiko Shirahige, Hitoshi Kurumizaka, Hiroshi Kimura, Yasuyuki Ohkawa. Nat Cell Biol 2019
77
50

The long non-coding RNA landscape in triple-negative breast cancer.
Wenwen Zhang, Xiaoxiang Guan, Jinhai Tang. Cell Prolif 2021
23
50


The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019.
Annalisa Buniello, Jacqueline A L MacArthur, Maria Cerezo, Laura W Harris, James Hayhurst, Cinzia Malangone, Aoife McMahon, Joannella Morales, Edward Mountjoy, Elliot Sollis,[...]. Nucleic Acids Res 2019
50


Pharmacogenomics: bench to bedside.
Richard Weinshilboum, Liewei Wang. Nat Rev Drug Discov 2004
183
50




Pharmacogenomics of breast cancer therapy: an update.
Kelly Westbrook, Vered Stearns. Pharmacol Ther 2013
27
50

Moving towards individualized medicine with pharmacogenomics.
William E Evans, Mary V Relling. Nature 2004
482
50

The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation.
Xi Jin, Xiao-En Xu, Yi-Zhou Jiang, Yi-Rong Liu, Wei Sun, Ya-Jie Guo, Yi-Xing Ren, Wen-Jia Zuo, Xin Hu, Sheng-Lin Huang,[...]. Sci Adv 2019
61
50

Noncoding RNA therapeutics - challenges and potential solutions.
Melanie Winkle, Sherien M El-Daly, Muller Fabbri, George A Calin. Nat Rev Drug Discov 2021
308
50

Epi-drugs as triple-negative breast cancer treatment.
Mouhamed Idrissou, Anna Sanchez, Frédérique Penault-Llorca, Yves-Jean Bignon, Dominique Bernard-Gallon. Epigenomics 2020
5
50

Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
Amita M Vaidya, Zhanhu Sun, Nadia Ayat, Andrew Schilb, Xujie Liu, Hongfa Jiang, Da Sun, Josef Scheidt, Victoria Qian, Siyuan He,[...]. Bioconjug Chem 2019
90
50

Health-promoting role of dietary bioactive compounds through epigenetic modulations: a novel prophylactic and therapeutic approach.
Ankita Kumari, Shalaka Bhawal, Suman Kapila, Hariom Yadav, Rajeev Kapila. Crit Rev Food Sci Nutr 2022
9
50




Identification of essential genes for cancer immunotherapy.
Shashank J Patel, Neville E Sanjana, Rigel J Kishton, Arash Eidizadeh, Suman K Vodnala, Maggie Cam, Jared J Gartner, Li Jia, Seth M Steinberg, Tori N Yamamoto,[...]. Nature 2017
473
50

Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns.
Shumei Zhang, Yihan Wang, Yue Gu, Jiang Zhu, Ce Ci, Zhongfu Guo, Chuangeng Chen, Yanjun Wei, Wenhua Lv, Hongbo Liu,[...]. Mol Oncol 2018
49
50

Emerging roles of long non-coding RNAs in breast cancer biology and management.
I Amelio, F Bernassola, E Candi. Semin Cancer Biol 2021
37
50



MicroRNAs in breast cancer: Roles, functions, and mechanism of actions.
Maryam Abolghasemi, Sadra Samavarchi Tehrani, Tooba Yousefi, Ansar Karimian, Ata Mahmoodpoor, Aliakbar Ghamari, Farhad Jadidi-Niaragh, Mehdi Yousefi, Hossein Samadi Kafil, Milad Bastami,[...]. J Cell Physiol 2020
48
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.